In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Two in three adults could be obese by 2050, according to world heart report (EMB Sat 17th 00:00) - More than 800 million ...

On Wall Street, Charter Communications rose 1.8% after it said it agreed to merge with Cox Communications in a deal that ...

Stocks closed solidly higher on Friday, pushing major indexes to big weekly gains for the third time in the last four weeks.

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get ...

Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...